Scarica l'app Stockscreener
14.20
2.54%
-0.37
Dopo l'orario di chiusura:
14.20
Precedente Chiudi:
$14.57
Aprire:
$14.31
Volume 24 ore:
45,736
Relative Volume:
0.66
Capitalizzazione di mercato:
$2.47B
Reddito:
$549.97M
Utile/perdita netta:
$458.86M
Rapporto P/E:
5.4124
EPS:
2.6236
Flusso di cassa netto:
$-89.06M
1 W Prestazione:
+1.87%
1M Prestazione:
+17.94%
6M Prestazione:
-7.91%
1 anno Prestazione:
-11.91%
Intervallo 1D:
$14.10
$14.34
Intervallo di 1 settimana:
$13.93
$14.93
Portata 52W:
$9.77
$16.40
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.20 | 2.42B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-11-24 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-05-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-08-03 | Iniziato | Jefferies | Buy |
| 2020-10-02 | Iniziato | Deutsche Bank | Buy |
| 2020-03-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-20 | Iniziato | Goldman | Buy |
| 2019-11-19 | Iniziato | CLSA | Buy |
| 2019-10-23 | Reiterato | BofA/Merrill | Buy |
| 2019-07-05 | Iniziato | Macquarie | Outperform |
Mostra tutto
Hutchmed China Limited Adr Borsa (HCM) Ultime notizie
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer - GlobeNewswire Inc.
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - The Manila Times
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseShould You Buy? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Trinity Delta Lighthouse: HUTCHMED - Vox Markets
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
HUTCHMED (China) LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - MarketBeat
Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com
GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy - GlobeNewswire
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. ADS each representing 10 (PHAR) Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat
HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media
HUTCHMED (HCM) lung cancer combo tops China Phase III trial - Stock Titan
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com
Neuraxis Inc. (NRXS) Peer Comparison – Compare with Others - Value Research
ProMIS Neurosciences Inc. (PMN) Peer Comparison – Compare with Others - Value Research
China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView
HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan
HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn
HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com
REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth - finance.yahoo.com
A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (NASDAQ:HCM) Stock Price Down 6%Here's Why - MarketBeat
Sea Limited Sponsored ADR (SE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Price to sales forward of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView
HCM Stock Price, Quote & Chart - ChartMill
Sea Limited Sponsored ADR (SE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan
HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire
Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan
HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire
HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView
H7T1 Forecast — Price Target — Prediction for 2027 - TradingView
Hutchmed China Limited Adr Azioni (HCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):